Biogen, PDL BioPharma say daclizumab trial meets main goal

March 12 (Reuters) - Biogen Idec Inc. (BIIB.O) and PDL BioPharma Inc. (PDLI.O) said the ongoing mid-stage trial of daclizumab, a humanized monoclonal antibody, met its main goal in relapsing multiple sclerosis .

In a statement, the companies said the anti-IL-2 receptor antibody significantly reduced the number of new or enlarged lesions compared to the dummy drug.

The companies plan to initiate a mid-stage monotherapy trial of daclizumab.

(Reporting by Deepti Chaudhary in Bangalore)

((Editing by Anil D'Silva; Reuters Messaging: deepti.chaudhary.reuters@reuters.net: within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800)) Keywords: BIOGEN TRIAL/

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWNAS3666